Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US98937L1052
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG01J1MG9D6
ZBIO
Zenas BioPharma, Inc.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
Zenas BioPharma, Inc.
ISIN
US98937L1052
TICKER
ZBIO
MIC
XNAS
REUTERS
ZBIO.OQ
BLOOMBERG
ZBIO US
Thu, 12.06.2025       Zenas BioPharma
US98937L1052

NEW YORK, June 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Wed, 11.06.2025       Zenas BioPharma
US98937L1052

LOS ANGELES, June 11, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Zenas Biopharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws. Shareho...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Tue, 10.06.2025       Zenas BioPharma
US98937L1052

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zenas To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Zenas pursuant and/or traceable to Zenas' registration statement for the initial public offering held on or about September 13...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Tue, 10.06.2025       Zenas BioPharma
US98937L1052

NEW YORK, June 10, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The law...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 09.06.2025       Zenas BioPharma
US98937L1052

LOS ANGELES  , June 9, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zenas BioPharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws....
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 09.06.2025       Zenas BioPharma
US98937L1052

NEW YORK, June 9, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 09.06.2025       Zenas BioPharma
US98937L1052

SAN DIEGO, June 9, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma's registration statement issued in connection with Zenas BioPharma's initial public offering (the "IPO") held on or around September 13,...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Sat, 07.06.2025       Zenas BioPharma
US98937L1052

  NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail ar...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Fri, 06.06.2025       Zenas BioPharma
US98937L1052

NEW YORK, June 6, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Fri, 06.06.2025       Zenas BioPharma
US98937L1052

LOS ANGELES, June 6, 2025 /PRNewswire/ --  The DJS Law Group reminds investors of a class action lawsuit against Zenas Biopharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws. Shareho...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Fri, 06.06.2025       Zenas BioPharma
US98937L1052

LOS ANGELES, June 6, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zenas BioPharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws....
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Fri, 06.06.2025       Zenas BioPharma
US98937L1052

NEW YORK, June 6, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The laws...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Thu, 05.06.2025       Zenas BioPharma
US98937L1052

NEW YORK, June 5, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Wed, 04.06.2025       Zenas BioPharma
US98937L1052

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Zenas To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Zenas pursuant and/or traceable to Zenas' registration statement for the initial public offering held on or...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.06.2025       Zenas BioPharma
US98937L1052

LOS ANGELES, June 2, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zenas BioPharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws....
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.06.2025       Zenas BioPharma
US98937L1052

LOS ANGELES, June 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Zenas Biopharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws. Sharehol...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.06.2025       Zenas BioPharma
US98937L1052

SAN DIEGO, June 2, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma's registration statement issued in connection with Zenas BioPharma's initial public offering ("IPO") held on or around S...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Sun, 01.06.2025       Zenas BioPharma
US98937L1052

NEW YORK, June 1, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Sat, 31.05.2025       Zenas BioPharma
US98937L1052

NEW YORK, May 31, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Sat, 31.05.2025       Zenas BioPharma
US98937L1052

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zenas To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Zenas pursuant and/or traceable to Zenas' registration statement for the initial public offering held on or about September 13...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Fri, 30.05.2025       Zenas BioPharma
US98937L1052

NEW YORK, May 30, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The laws...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Thu, 29.05.2025       Zenas BioPharma
US98937L1052

NEW YORK, May 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Thu, 29.05.2025       Zenas BioPharma
US98937L1052

WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced management’s presentation at the Jefferies Global Healthcare...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Wed, 28.05.2025       Zenas BioPharma
US98937L1052

LOS ANGELES, May 28, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zenas BioPharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws....
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Wed, 28.05.2025       Zenas BioPharma
US98937L1052

LOS ANGELES, May 28, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Zenas Biopharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws. Sharehol...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Wed, 28.05.2025       Zenas BioPharma
US98937L1052

SAN DIEGO, May 27, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons who purchased or otherwise acquired Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma's September 202...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Tue, 27.05.2025       Zenas BioPharma
US98937L1052

SAN DIEGO, May 27, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma's registration statement issued in connection with Zenas BioPharma's initial public offering ("IPO") held on or around September 13, 202...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Tue, 27.05.2025       Zenas BioPharma
US98937L1052

LOS ANGELES, May 27, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zenas BioPharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws....
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 26.05.2025       Zenas BioPharma
US98937L1052

NEW YORK, May 26, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are e...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 26.05.2025       Zenas BioPharma
US98937L1052

NEW YORK, May 26, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Fri, 23.05.2025       Zenas BioPharma
US98937L1052

LOS ANGELES, May 23, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zenas BioPharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws....
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Fri, 23.05.2025       Zenas BioPharma
US98937L1052

NEW YORK, May 23, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The laws...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Thu, 22.05.2025       Zenas BioPharma
US98937L1052

NEW YORK, May 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Thu, 22.05.2025       Zenas BioPharma
US98937L1052

NEW YORK, May 21, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Tue, 20.05.2025       Zenas BioPharma
US98937L1052

NEW YORK, May 20, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Tue, 20.05.2025       Zenas BioPharma
US98937L1052

NEW YORK, May 20, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The laws...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 19.05.2025       Zenas BioPharma
US98937L1052

NEW YORK, May 19, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 19.05.2025       Zenas BioPharma
US98937L1052

LOS ANGELES, May 19, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zenas BioPharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws....
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 19.05.2025       Zenas BioPharma
US98937L1052

SAN DIEGO, May 19, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma's registration statement issued in connection with Zenas BioPharma's initial public offering (the "IPO") held on or around September 13,...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Fri, 16.05.2025       Zenas BioPharma
US98937L1052

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Zenas To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Zenas pursuant and/or traceable to Zenas' registration statement for the initial public offering held on or...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Fri, 16.05.2025       Zenas BioPharma
US98937L1052

NEW YORK, May 16, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The laws...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Thu, 15.05.2025       Zenas BioPharma
US98937L1052

NEW YORK, May 15, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Thu, 15.05.2025       Zenas BioPharma
US98937L1052

NEW YORK, May 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Thu, 15.05.2025       Zenas BioPharma
US98937L1052

- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 -...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Tue, 13.05.2025       Zenas BioPharma
US98937L1052

NEW YORK, May 13, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The laws...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 12.05.2025       Zenas BioPharma
US98937L1052

NEW YORK, May 12, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement an...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 12.05.2025       Zenas BioPharma
US98937L1052

NEW YORK, May 12, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 12.05.2025       Zenas BioPharma
US98937L1052

LOS ANGELES, May 12, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zenas BioPharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws....
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 12.05.2025       Zenas BioPharma
US98937L1052

NEW YORK, May 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Fri, 09.05.2025       Zenas BioPharma
US98937L1052

NEW YORK, May 9, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The lawsu...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink